

## Medical Policy Manual **Approved Rev: Do Not Implement until 4/30/26**

### **Lurbinectedin (Zepzelca®)**

#### **IMPORTANT REMINDER**

We develop Medical Policies to provide guidance to Members and Providers. This Medical Policy relates only to the services or supplies described in it. The existence of a Medical Policy is not an authorization, certification, explanation of benefits or a contract for the service (or supply) that is referenced in the Medical Policy. For a determination of the benefits that a Member is entitled to receive under his or her health plan, the Member's health plan must be reviewed. If there is a conflict between the medical policy and a health plan or government program (e.g., TennCare), the express terms of the health plan or government program will govern.

#### **POLICY**

#### **INDICATIONS**

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

##### FDA-Approved Indications

Zepzelca is indicated:

- In combination with atezolizumab or atezolizumab and hyaluronidase-tqjs, for the maintenance treatment of adult patients with extensive-stage small cell lung cancer whose disease has not progressed after first-line induction therapy with atezolizumab or atezolizumab and hyaluronidase-tqjs, carboplatin and etoposide
- for the treatment of adult patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy.

##### Compendial Uses

- Relapsed small cell lung cancer
- Primary progressive small cell lung cancer

All other indications are considered experimental/investigational and not medically necessary.

#### **COVERAGE CRITERIA**

##### **Small Cell Lung Cancer**

Authorization of 12 months may be granted for treatment of small cell lung cancer in any of the following **regimens**:

- **As a single agent for subsequent treatment of any of the following:**
  - Relapse following complete or partial response or stable disease with initial treatment
  - Primary progressive disease
  - Metastatic disease following disease progression on or after platinum-based chemotherapy
- In combination with atezolizumab or atezolizumab and hyaluronidase-tqjs as maintenance treatment for extensive stage disease if no progression after first-line induction therapy with atezolizumab or atezolizumab and hyaluronidase-tqjs, carboplatin and etoposide

#### **CONTINUATION OF THERAPY**



## Medical Policy Manual **Approved Rev: Do Not Implement until 4/30/26**

Authorization of 12 months may be granted for continued treatment in members requesting reauthorization for an indication listed in the coverage criteria section when there is no evidence of unacceptable toxicity or disease progression while on the current regimen.

### **APPLICABLE TENNESSEE STATE MANDATE REQUIREMENTS**

BlueCross BlueShield of Tennessee's Medical Policy complies with Tennessee Code Annotated Section 56-7-2352 regarding coverage of off-label indications of Food and Drug Administration (FDA) approved drugs when the off-label use is recognized in one of the statutorily recognized standard reference compendia or in the published peer-reviewed medical literature.

### **ADDITIONAL INFORMATION**

For appropriate chemotherapy regimens, dosage information, contraindications, precautions, warnings, and monitoring information, please refer to one of the standard reference compendia (e.g., the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) published by the National Comprehensive Cancer Network®, Drugdex Evaluations of Micromedex Solutions at Truven Health, or The American Hospital Formulary Service Drug Information).

### **REFERENCES**

1. Zepzelca [package insert]. Palo Alto, CA: Jazz Pharmaceuticals, Inc.; **October** 2025.
2. The NCCN Drugs & Biologics Compendium® © 2025 National Comprehensive Cancer Network, Inc. <https://www.nccn.org>. Accessed **October 22**, 2025.

### **EFFECTIVE DATE**

9/1/2020	(8/11/20 - Approved by P&T Corporate Subcommittee)
11/2/2021	(8/10/21 - Approved by P&T Corporate Subcommittee)
7/12/2022	(7/12/22 - Maintenance / P&T Corporate Subcommittee)
4/11/2023	(4/11/23 - Maintenance / P&T Corporate Subcommittee)
1/1/2024	(10/10/23 - CHS - Approved by P&T Corporate Subcommittee)
5/14/2024	(5/14/24 - Maintenance / P&T Corporate Subcommittee)
1/14/2025	(1/14/25 - Maintenance / P&T Corporate Subcommittee)
1/13/2026	(1/13/26 - Maintenance / P&T Corporate Subcommittee)
4/30/2026	(2/10/26 - Approved by P&T Corporate Subcommittee)

ID\_CHS\_2025a